

MANNKIND CORP  
Form 8-K  
September 16, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 16, 2008**

**MannKind Corporation**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**000-50865**

(Commission File Number)

**13-3607736**

(IRS Employer  
Identification No.)

**28903 North Avenue Paine**

**Valencia, California**

(Address of principal executive offices)

**91355**

(Zip Code)

Registrant's telephone number, including area code: **(661) 775-5300**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Section 8 Other Events**

**Item 8.01 Other Events**

On September 16, 2008, MannKind Corporation issued a press release announcing results from a phase 3 clinical study of Technosphere<sup>®</sup> Insulin. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

On September 16, 2008, MannKind Corporation and Pfizer Inc. issued a joint press release announcing a collaboration to transition certain Exubera patients to MannKind's Technosphere<sup>®</sup> Insulin therapy. A copy of the press release is filed as Exhibit 99.2 to this report and is incorporated herein by reference.

**Section 9 Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits.

Number	Description
99.1	Press Release of MannKind Corporation dated September 16, 2008, reporting MannKind's results from a phase 3 clinical study of Technosphere <sup>®</sup> Insulin.
99.2	Press Release of MannKind Corporation and Pfizer Inc. dated September 16, 2008, announcing collaboration to transition certain Exubera patients to MannKind's Technosphere <sup>®</sup> Insulin therapy.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MANNKIND CORPORATION**

By: /s/ David Thomson

Name: David Thomson, Ph.D., J.D.

Title: Corporate Vice President, General  
Counsel and Secretary

Dated: September 16, 2008

---

**EXHIBIT INDEX**

<b>Number</b>	<b>Description</b>
99.1	Press Release of MannKind Corporation dated September 16, 2008, reporting MannKind's results from a phase 3 clinical study of Technosphere <sup>®</sup> Insulin.
99.2	Press Release of MannKind Corporation and Pfizer Inc. dated September 16, 2008, announcing collaboration to transition certain Exubera patients to MannKind's Technosphere <sup>®</sup> Insulin therapy.